SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

Their core work

Sanofi R&D is the research and development arm of Sanofi, one of the world's largest pharmaceutical companies, headquartered in France. Within H2020, they contribute deep drug development expertise, clinical trial infrastructure, and translational safety knowledge to large-scale public-private partnerships — particularly through the Innovative Medicines Initiative (IMI). Their work spans preclinical safety assessment, biomarker discovery, real-world evidence generation, and digital health data standardization, consistently bridging the gap between laboratory science and patient outcomes. They bring industry-scale compound libraries, patient cohort access, and regulatory experience that academic partners typically lack.

What they specialise in

How they've shifted over time

In 2015–2018, Sanofi R&D's H2020 portfolio centered on foundational drug development themes: cancer biology (epigenetics, systems biology), adaptive regulatory pathways (ADAPT-SMART), and preclinical data quality. From 2019 onward, their focus shifted markedly toward digital health endpoints, decentralized clinical trials, immune safety modeling, and sustainability of research platforms. This evolution mirrors the broader pharma industry's pivot from traditional bench-to-bedside research toward data-driven, patient-centric, and computationally intensive drug development.

Sanofi R&D is moving toward computational and digital approaches to drug safety and clinical endpoints, making them a strong partner for projects combining AI, real-world data, and regulatory science.

How they like to work

Sanofi R&D operates exclusively as a participant or third party — they have not coordinated any of their 37 H2020 projects, which is typical for large pharma in IMI-style public-private partnerships where academic or SME partners take the coordination role. They engage in very large consortia (598 unique partners across 35 countries), indicating a hub-like network position where they contribute industry data, compounds, and regulatory know-how rather than project management. Working with them means gaining access to pharma-scale resources and validation capabilities, but expect them to contribute within defined work packages rather than drive overall project direction.

With 598 unique consortium partners across 35 countries, Sanofi R&D has one of the broadest collaborative networks in H2020 health research, spanning nearly all EU member states plus associated countries. Their network is particularly dense in IMI consortia connecting pharma, academia, regulators, and patient organizations.

What sets them apart

As a top-5 global pharma company's R&D division, Sanofi brings something most H2020 partners cannot: direct access to proprietary compound libraries, large-scale clinical trial data, and firsthand regulatory submission experience. Their consistent participation across 37 projects — without coordinating any — means they are a reliable, low-friction industry partner that delivers domain expertise without competing for project leadership. For consortium builders, adding Sanofi R&D signals credibility to reviewers and provides genuine translational muscle to move research findings toward clinical application.

Highlights from their portfolio

• EHDEN
  One of IMI's flagship health data projects, building a federated network of 100+ data partners using the OMOP common data model — directly shaping how real-world evidence is generated across Europe.
• IMMUcan
  Large-scale immuno-oncology project running until 2026 that integrates deep immunophenotyping (CyTOF, RNAseq) across multiple cancer types — a rare multi-tumor immune profiling effort.
• CUPIDO
  Their highest-funded project (EUR 219,909) and an unusual departure into nanomedicine and cardiovascular drug delivery via inhalation, sitting at the intersection of manufacturing and health.